The 3D-PREDICT clinical study analyses a patient's live cancer cells, grown in Kiyatec's laboratory within a biologically-relevant 3D microenvironment, to determine whether those cells respond to guideline-recommended cancer drugs.
Evidence from the company's earlier pilot study established a correlation between patient-specific predicted tumor response and actual patient clinical response to cancer therapy.
The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.
The 3D-PREDICT study is anticipated to continue through 2022.
Inova has already accrued patients into the trial and G. Larry Maxwell, MD, chairman of Obstetrics and Gynecology and co-director of Inova's Women's Health Integrated Research Center (WHIRC) is the lead investigator.
Inova Strategic Investments, the strategic investing division of the Inova Health System, is an investor in Kiyatec.
The division invests in companies that align with Inova's strategic priorities of delivering personalized health and healthcare services.
Kiyatec develops 3D cell-based assays for use in preclinical drug discovery and clinical therapy applications. It has a contract research project portfolio performing standard and custom cell-based assays for biopharma clients, as well as research and development contracts funded by the National Cancer Institute to develop 3D cell culture models for breast cancer, glioblastoma, and lung cancer.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval